GTBP News and Press, GT Biopharma Inc. From 11/01/23

IND submission for GTB-3650, 2 nd generation nanobody TriKE ® for treatment of CD33+ leukemia, expected in Q4 2023 Phase 1 clinical trial initiation evaluating GTB-3650 for treatment of CD33+ leukemia anticipated in 2024 Cash of approximately $16 million a...

FMC Corporation (FMC) is expected to report $0.45 for Q3 2023 NCS Multistage Holdings Inc. (NCSM) is expected to report $2.59 for Q3 2023 Third Century Bancorp (TDCB) is expected to report for Q3 2023 ZoomInfo Technologies Inc. (ZI) is expected to report $0.15 for Q3 2023 Matson I...

GT Biopharma Inc. (GTBP) is expected to report $-0.1 for Q3 2023

2023-08-07 10:52:09 ET GT Biopharma press release ( NASDAQ: GTBP ): Q2 GAAP EPS of -$0.05. The Company had cash, cash equivalents and short-term investments of $18.0 million as of June 30, 2023, compared to $16.5 million as of December 31, 2022. For further details s...

C ash of approximately $ 1 8.0 million as of June 30 , 202 3 , provide s ample runway to fund operations into Q 3 202 4; anticipated to b e sufficient to achieve IND clearance for GTB-3650 and initiate clinical trial ...

BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE ® platform, today announced that Dr...

2023-05-15 17:33:22 ET GT Biopharma press release ( NASDAQ: GTBP ): Q1 GAAP EPS of -$0.01 beats by $0.15 . The Company had cash, cash equivalents and short-term investments of $19.9 million as of March 31, 2023, compared to $16.5 million as of December 31, 2022. This i...

C ash of approximately $ 19.9 million as of March 31, 202 3 , provide s ample runway to fund operations into Q2 202 4; anticipated to b e sufficient to achieve IND clearance for GTB-3650 and GTB-5550 , and initiate cl...

BRISBANE, CALIFORNIA, May 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE ®...

Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31, 2022, plus $6.5 million in gross proceeds received from a registered direct offering priced at a premium to market on January 4, 2023. Cash on hand, coupled with significant recent cost redu...